 <a id="main-content" tabindex="-1"></a>  [  Care pathway for liver cancer ](/en/patient/treatments-and-examinations/cancer/care-pathway-liver-cancer#if-the-disease-recurs-or-treat)---



#  Treatment of metastatic hepatocellular carcinoma 

The treatment of metastatic hepatocellular carcinoma aims to slow down the disease and maintain as good a quality of life as possible and, in some cases, prolong life expectancy.

If the cancer recurs after liver surgery, we can continue to treat it with local therapies on a case-by-case basis. As a rule, the prerequisite is that the cancer has not spread beyond the liver.

 



 

##   Drug therapy in the treatment of metastatic hepatocellular carcinoma    

---

If local treatments or surgical treatment are not possible or the cancer has already spread when diagnosed, we will consider the possibility of drug treatment.

We carry out drug treatments for hepatocellular carcinoma intravenously or in tablet form. Sometimes different drugs may be combined in the treatment. In some patients, the drugs can cause adverse effects that prevent or limit the administering of drug therapy. We can also use medication to alleviate the symptoms caused by liver cancer, such as nausea and possible pain.

Of pharmacotherapies, chemotherapy is not effective in the treatment of metastatic or recurrent liver cancer.

 



 



##   Radiation therapy in the treatment of metastatic hepatocellular carcinoma    

---

If the spread of the tumor causes pain, we can use radiation therapy as a form of treatment. Radiation therapy may also be appropriate for the treatment of localized liver tumors if other treatment options are not possible. The use of radiation therapy is limited by the fact that healthy liver tissue reacts sensitively to radiation therapy.

 



 



 

  

 ##  Phase of the service path 

      

 

##  From symptoms to diagnosis 

 



      

 

##  Getting a diagnosis 

 



      

 

##  Treatments 

 



      

 

##  After treatments 

 



Paragraph

 

 

  

  Updated: 06.02.2024

   Print this page